Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Sotagliflozin (formerly known as LP-80203; LX4211; LP80203; LX-4211; Zynquista; Inpefa), an antidiabetic drug approved for treating type 1 diabetes in EU, is a potent, orally bioavailable, and dual SGLT1/SGLT2 inhibitor with antidiabetic activity. It blocks SGLT1/SGLT2 with IC50s of 36 nM and 1.8 nM, respectively. In a randomized, placebo-controlled study, sotagliflozin helps patients with type 2 diabetes achieve better glycemic control. By inhibiting the intestinal glucose absorption mediated by sodium/glucose cotransporter 1 (SGLT1), sotagliflozin also raises serum levels of peptide YY and glucagon-like peptide 1. Sotagliflozin (Inpefa) was approved in 2023 by FDA for treating Heart failure.
Targets |
SGLT1/2
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
|
Molecular Formula |
C21H25CLO5S
|
|
---|---|---|
Molecular Weight |
424.94
|
|
Exact Mass |
424.11
|
|
Elemental Analysis |
C, 59.36; H, 5.93; Cl, 8.34; O, 18.83; S, 7.55
|
|
CAS # |
1018899-04-1
|
|
Appearance |
White to off-white solid powder
|
|
SMILES |
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
|
|
InChi Key |
QKDRXGFQVGOQKS-CRSSMBPESA-N
|
|
InChi Code |
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
|
|
Chemical Name |
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3533 mL | 11.7664 mL | 23.5327 mL | |
5 mM | 0.4707 mL | 2.3533 mL | 4.7065 mL | |
10 mM | 0.2353 mL | 1.1766 mL | 2.3533 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05405556 | Recruiting | Diagnostic Test: eGFR reporting | Kidney Transplant | Martina McGrath, MD | October 17, 2022 | Phase 2 |
NCT05562063 | Recruiting | Drug: Sotagliflozin Drug: Placebo |
Heart Failure With Preserved Ejection Fraction |
Juan Badimon | October 26, 2022 | Phase 4 |
NCT06217302 | Not yet recruiting | Drug: Sotagliflozin Drug: Placebo |
Diabetic Nephropathies Kidney Failure, Chronic |
Alessandro Doria | May 2024 | Phase 3 |
NCT06147232 | Not yet recruiting | Drug: Sotagliflozin Drug: Placebo |
Nephropathy Albuminuria |
Steno Diabetes Center Copenhagen |
February 2024 | Phase 4 |
NCT05696366 | Not yet recruiting | Drug: Sotagliflozin Drug: Volagidemab |
Type 1 Diabetes | University of California, San Diego |
February 2023 | Phase 1 Phase 2 |